BioCentury
ARTICLE | Company News

Eagle Pharmaceuticals, Teva deal

December 21, 2015 8:00 AM UTC

Eagle received a $15 million milestone payment from Teva under a 2015 deal granting Teva exclusive, U.S. rights to commercialize Bendeka bendamustine to treat chronic lymphocytic leukemia (CLL) and i...